Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial
Abstract Relapse remains a major challenge for high-risk acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). In our first-in-human Phase I trial (ChiCTR-1900022795), we have demonstrated that third-party donor-derived double-negative T cell...
Saved in:
| Main Authors: | Guangyu Sun, Xingchi Chen, Tianzhong Pan, Kaidi Song, Haicun Xie, Meijuan Tu, Xiang Wan, Wen Yao, Yaxin Cheng, Ziwei Zhou, Dongyao Wang, Yongsheng Han, Baolin Tang, Liming Yang, Xiaoyu Zhu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-025-00680-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Decitabine Conditioning on Allo‐HSCT Outcomes in AML and Intermediate‐to‐High‐Risk MDS Patients in Remission
by: Shuling Yu, et al.
Published: (2025-07-01) -
Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy
by: Wen-Jing Yu, et al.
Published: (2024-12-01) -
Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion
by: Eva A. S. Koster, et al.
Published: (2023-08-01) -
Correction: Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion
by: Eva A. S. Koster, et al.
Published: (2025-06-01) -
Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease
by: Can Chen, et al.
Published: (2025-12-01)